{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:14:46Z","timestamp":1791630886265,"version":"4.3.4"},"reference-count":198,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82274566"],"award-info":[{"award-number":["82274566"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-025-01864-3","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T09:38:41Z","timestamp":1763545121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Vascular endothelial generating factor pathway in ovarian cancer"],"prefix":"10.1186","volume":"18","author":[{"given":"Yuxin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaochu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keqing","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjuan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"issue":"6","key":"1864_CR1","first-page":"609","volume":"80","author":"MA Roett","year":"2009","unstructured":"Roett MA, Evans P. Ovarian cancer: an overview. Am Fam Physician. 2009;80(6):609\u201316.","journal-title":"Am Fam Physician"},{"issue":"3","key":"1864_CR2","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.bbrc.2015.11.134","volume":"469","author":"RR Somasagara","year":"2016","unstructured":"Somasagara RR, Tripathi K, Spencer SM, et al. Rad6 upregulation promotes stem cell-like characteristics and platinum resistance in ovarian cancer. Biochem Biophys Res Commun. 2016;469(3):449\u201355.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1864_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","volume":"35","author":"C Stewart","year":"2019","unstructured":"Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35(2):151\u20136.","journal-title":"Semin Oncol Nurs"},{"issue":"9","key":"1864_CR4","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s43018-023-00617-9","volume":"4","author":"PA Konstantinopoulos","year":"2023","unstructured":"Konstantinopoulos PA, Matulonis UA. Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 2023;4(9):1239\u201357.","journal-title":"Nat Cancer"},{"issue":"1","key":"1864_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01967-3","volume":"23","author":"L Wang","year":"2024","unstructured":"Wang L, Wang X, Zhu X, et al. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol Cancer. 2024;23(1):66.","journal-title":"Mol Cancer"},{"key":"1864_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577869","volume":"11","author":"C Yang","year":"2020","unstructured":"Yang C, Xia BR, Zhang ZC, et al. Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant. Front Immunol. 2020;11:577869.","journal-title":"Front Immunol"},{"issue":"1","key":"1864_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1757-2215-6-45","volume":"6","author":"S Lawicki","year":"2013","unstructured":"Lawicki S, B\u0119dkowska GE, Gacuta-Szumarska E, et al. The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors. J Ovarian Res. 2013;6(1):45.","journal-title":"J Ovarian Res"},{"issue":"1","key":"1864_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02779-x","volume":"42","author":"D Boso","year":"2023","unstructured":"Boso D, Tognon M, Curtarello M, et al. Anti-VEGF therapy selects for clones resistant to glucose starvation in ovarian cancer xenografts. J Exp Clin Cancer Res. 2023;42(1):196.","journal-title":"J Exp Clin Cancer Res"},{"key":"1864_CR9","doi-asserted-by":"publisher","first-page":"100954","DOI":"10.1016\/j.preteyeres.2021.100954","volume":"84","author":"A Uemura","year":"2021","unstructured":"Uemura A, Fruttiger M, D\u2019Amore PA, et al. VEGFR1 signaling in retinal angiogenesis and microinflammation. Prog Retin Eye Res. 2021;84:100954.","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"1864_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ygyno.2007.10.018","volume":"108","author":"A Bamias","year":"2008","unstructured":"Bamias A, Koutsoukou V, Terpos E, et al. Correlation of NK T-like CD3\u2009+\u2009CD56\u2009+\u2009cells and CD4\u2009+\u2009CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol Oncol. 2008;108(2):421\u20137.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1864_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138.","journal-title":"Mol Cancer"},{"issue":"29","key":"1864_CR12","doi-asserted-by":"publisher","first-page":"28491","DOI":"10.18632\/oncotarget.4427","volume":"6","author":"S Masoumi-Moghaddam","year":"2015","unstructured":"Masoumi-Moghaddam S, Amini A, Wei AQ, et al. Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer. Oncotarget. 2015;6(29):28491\u2013501.","journal-title":"Oncotarget"},{"key":"1864_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040783","author":"A \u015aliwa","year":"2024","unstructured":"\u015aliwa A, Szczerba A, Pi\u0119ta PP, et al. A recipe for successful metastasis: transition and migratory modes of ovarian cancer cells. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16040783.","journal-title":"Cancers (Basel)"},{"key":"1864_CR14","volume":"49","author":"FH Faria","year":"2022","unstructured":"Faria FH, Lage APD, Rodrigues AN, et al. Impact of proper surgical treatment on the survival of patients with epithelial ovary cancer. Rev Col Bras Cir. 2022;49:e20223231.","journal-title":"Rev Col Bras Cir"},{"issue":"3","key":"1864_CR15","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2020.31.e30","volume":"31","author":"BJ Mosgaard","year":"2020","unstructured":"Mosgaard BJ, Meaidi A, H\u00f8gdall C, et al. Risk factors for early death among ovarian cancer patients: a nationwide cohort study. J Gynecol Oncol. 2020;31(3):e30.","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"1864_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4339-0","volume":"18","author":"M Ramser","year":"2018","unstructured":"Ramser M, Eichelberger S, D\u00e4ster S, et al. High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy. BMC Cancer. 2018;18(1):425.","journal-title":"BMC Cancer"},{"issue":"Suppl 3","key":"1864_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000088478","volume":"69","author":"P Carmeliet","year":"2005","unstructured":"Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69(Suppl 3):4\u201310.","journal-title":"Oncology"},{"issue":"35","key":"1864_CR18","doi-asserted-by":"publisher","first-page":"8029","DOI":"10.1002\/anie.201103237","volume":"50","author":"K Mandal","year":"2011","unstructured":"Mandal K, Kent SB. Total chemical synthesis of biologically active vascular endothelial growth factor. Angew Chem Int Ed Engl. 2011;50(35):8029\u201333.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"36","key":"1864_CR19","doi-asserted-by":"publisher","first-page":"13203","DOI":"10.1073\/pnas.0806582105","volume":"105","author":"Y Cao","year":"2008","unstructured":"Cao Y, Langer R. A review of Judah Folkman\u2019s remarkable achievements in biomedicine. Proc Natl Acad Sci U S A. 2008;105(36):13203\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"1864_CR20","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.7150\/jca.44313","volume":"11","author":"CO Madu","year":"2020","unstructured":"Madu CO, Wang S, Madu CO, et al. Angiogenesis in breast cancer progression, diagnosis, and treatment. J Cancer. 2020;11(15):4474\u201394.","journal-title":"J Cancer"},{"key":"1864_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cells10081964","author":"AS Tarnawski","year":"2021","unstructured":"Tarnawski AS, Ahluwalia A. The critical role of growth factors in gastric ulcer healing: the cellular and molecular mechanisms and potential clinical implications. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10081964.","journal-title":"Cells"},{"key":"1864_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133513","author":"SM Ruff","year":"2023","unstructured":"Ruff SM, Shannon AH, Pawlik TM. The role of targeted therapy in the multi-disciplinary approach to colorectal liver metastasis. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15133513.","journal-title":"Cancers (Basel)"},{"key":"1864_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232214187","author":"M Matsui","year":"2022","unstructured":"Matsui M, Onoue K, Saito Y. Sflt-1 in chronic kidney disease: friend or foe? Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232214187.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1864_CR24","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1177\/1947601911423031","volume":"2","author":"M Shibuya","year":"2011","unstructured":"Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer. 2011;2(12):1097\u2013105.","journal-title":"Genes Cancer"},{"issue":"10","key":"1864_CR25","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009092","volume":"5","author":"M Shibuya","year":"2013","unstructured":"Shibuya M. VEGFR and type-V RTK activation and signaling. Cold Spring Harb Perspect Biol. 2013;5(10):a009092.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"7","key":"1864_CR26","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1054\/bjoc.2000.1396","volume":"83","author":"K Akagi","year":"2000","unstructured":"Akagi K, Ikeda Y, Miyazaki M, et al. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br J Cancer. 2000;83(7):887\u201391.","journal-title":"Br J Cancer"},{"issue":"4","key":"1864_CR27","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1152\/physrev.00006.2020","volume":"101","author":"S Martin-Almedina","year":"2021","unstructured":"Martin-Almedina S, Mortimer PS, Ostergaard P. Development and physiological functions of the lymphatic system: insights from human genetic studies of primary lymphedema. Physiol Rev. 2021;101(4):1809\u201371.","journal-title":"Physiol Rev"},{"issue":"1","key":"1864_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3892\/ijo.2016.3527","volume":"49","author":"X Qi","year":"2016","unstructured":"Qi X, Du L, Chen X, et al. VEGF-D-enhanced lymph node metastasis of ovarian cancer is reversed by vesicular stomatitis virus matrix protein. Int J Oncol. 2016;49(1):123\u201332.","journal-title":"Int J Oncol"},{"key":"1864_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7827-12-14","volume":"12","author":"LC Du","year":"2014","unstructured":"Du LC, Chen XC, Wang D, et al. VEGF-D-induced draining lymphatic enlargement and tumor lymphangiogenesis promote lymph node metastasis in a xenograft model of ovarian carcinoma. Reprod Biol Endocrinol. 2014;12:14.","journal-title":"Reprod Biol Endocrinol"},{"key":"1864_CR30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1146\/annurev.pharmtox.010909.105753","volume":"50","author":"JW Choi","year":"2010","unstructured":"Choi JW, Herr DR, Noguchi K, et al. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol. 2010;50:157\u201386.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"1864_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.coph.2008.03.003","volume":"8","author":"RM Tuder","year":"2008","unstructured":"Tuder RM, Yun JH. Vascular endothelial growth factor of the lung: friend or foe. Curr Opin Pharmacol. 2008;8(3):255\u201360.","journal-title":"Curr Opin Pharmacol"},{"issue":"3","key":"1864_CR32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1586\/14737159.2015.993972","volume":"15","author":"KM Marien","year":"2015","unstructured":"Marien KM, Croons V, Martinet W, et al. Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update. Expert Rev Mol Diagn. 2015;15(3):399\u2013414.","journal-title":"Expert Rev Mol Diagn"},{"issue":"5","key":"1864_CR33","first-page":"444","volume":"62","author":"D Kajdaniuk","year":"2011","unstructured":"Kajdaniuk D, Marek B, Borgiel-Marek H, et al. Vascular endothelial growth factor (VEGF) - part 1: in physiology and pathophysiology. Endokrynol Pol. 2011;62(5):444\u201355.","journal-title":"Endokrynol Pol"},{"issue":"4","key":"1864_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005108","volume":"4","author":"FT Wu","year":"2009","unstructured":"Wu FT, Stefanini MO, Mac Gabhann F, et al. A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap. PLoS ONE. 2009;4(4):e5108.","journal-title":"PLoS ONE"},{"issue":"6","key":"1864_CR35","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1158\/1541-7786.315.2.6","volume":"2","author":"JM Ebos","year":"2004","unstructured":"Ebos JM, Bocci G, Man S, et al. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res. 2004;2(6):315\u201326.","journal-title":"Mol Cancer Res"},{"issue":"8","key":"1864_CR36","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/emboj.2010.30","volume":"29","author":"I Nilsson","year":"2010","unstructured":"Nilsson I, Bahram F, Li X, et al. VEGF receptor 2\/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts. EMBO J. 2010;29(8):1377\u201388.","journal-title":"EMBO J"},{"issue":"10","key":"1864_CR37","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1177\/154405910708601006","volume":"86","author":"J Dai","year":"2007","unstructured":"Dai J, Rabie AB. VEGF: an essential mediator of both angiogenesis and endochondral ossification. J Dent Res. 2007;86(10):937\u201350.","journal-title":"J Dent Res"},{"issue":"2","key":"1864_CR38","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.3892\/mmr.2015.3752","volume":"12","author":"J Lu","year":"2015","unstructured":"Lu J, Cheng Y, Zhang G, et al. Increased expression of neuropilin 1 in melanoma progression and its prognostic significance in patients with melanoma. Mol Med Rep. 2015;12(2):2668\u201376.","journal-title":"Mol Med Rep"},{"key":"1864_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010072","author":"AK Puszko","year":"2020","unstructured":"Puszko AK, Sosnowski P, Rignault-Bricard R, et al. Urea-peptide hybrids as VEGF-A(165)\/NRP-1 complex inhibitors with improved receptor affinity and biological properties. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms22010072.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1864_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8030350","volume":"8","author":"A Parveen","year":"2019","unstructured":"Parveen A, Subedi L, Kim HW, et al. Phytochemicals targeting VEGF and VEGF-related multifactors as anticancer therapy. J Clin Med. 2019;8(3):350.","journal-title":"J Clin Med"},{"issue":"6","key":"1864_CR41","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0092-8674(00)81402-6","volume":"92","author":"S Soker","year":"1998","unstructured":"Soker S, Takashima S, Miao HQ, et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998;92(6):735\u201345.","journal-title":"Cell"},{"issue":"7471","key":"1864_CR42","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333\u20139.","journal-title":"Nature"},{"key":"1864_CR43","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","volume":"59","author":"MK Ediriweera","year":"2019","unstructured":"Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance. Semin Cancer Biol. 2019;59:147\u201360.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"1864_CR44","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3390\/receptors3020008","volume":"3","author":"L Toffoli","year":"2024","unstructured":"Toffoli L, Ditsiou A, Gagliano T. Exploring emerging therapeutic targets and opportunities in neuroendocrine tumors: updates on receptor tyrosine kinases. Receptors. 2024;3(2):145\u201354.","journal-title":"Receptors"},{"key":"1864_CR45","doi-asserted-by":"publisher","first-page":"818","DOI":"10.2741\/1839","volume":"11","author":"N Rahimi","year":"2006","unstructured":"Rahimi N. VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Front Biosci. 2006;11:818\u201329.","journal-title":"Front Biosci"},{"key":"1864_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/genes12020174","author":"RO Snodgrass","year":"2021","unstructured":"Snodgrass RO, Chico TJA, Arthur HM. Hereditary haemorrhagic telangiectasia, an inherited vascular disorder in need of improved evidence-based pharmaceutical interventions. Genes. 2021. https:\/\/doi.org\/10.3390\/genes12020174.","journal-title":"Genes"},{"issue":"10","key":"1864_CR47","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1210\/me.2004-0082","volume":"18","author":"R Steinmetz","year":"2004","unstructured":"Steinmetz R, Wagoner HA, Zeng P, et al. Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1\/2 on cancer cell proliferation. Mol Endocrinol. 2004;18(10):2570\u201382.","journal-title":"Mol Endocrinol"},{"issue":"3","key":"1864_CR48","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5551\/jat.13.130","volume":"13","author":"T Matsumoto","year":"2006","unstructured":"Matsumoto T, Mugishima H. Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis. J Atheroscler Thromb. 2006;13(3):130\u20135.","journal-title":"J Atheroscler Thromb"},{"key":"1864_CR49","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.2147\/OTT.S60114","volume":"7","author":"D Vyas","year":"2014","unstructured":"Vyas D, Laput G, Vyas AK. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. Onco Targets Ther. 2014;7:1015\u201323.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"1864_CR50","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.gendis.2023.02.039","volume":"11","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Xing C, Deng Y, et al. HIF-1\u03b1 signaling: essential roles in tumorigenesis and implications in targeted therapies. Genes Dis. 2024;11(1):234\u201351.","journal-title":"Genes Dis"},{"issue":"1","key":"1864_CR51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.5114\/pjp.2021.106441","volume":"72","author":"M Alabiad","year":"2021","unstructured":"Alabiad M, Harb O, Mandour D, et al. Prognostic and clinicopathological implications of expression of Beclin-1 and hypoxia-inducible factor 1\u03b1 in serous ovarian carcinoma: an immunohistochemical study. Pol J Pathol. 2021;72(1):23\u201338.","journal-title":"Pol J Pathol"},{"issue":"3","key":"1864_CR52","first-page":"449","volume":"28","author":"SB Choi","year":"2011","unstructured":"Choi SB, Park JB, Song TJ, et al. Molecular mechanism of HIF-1-independent VEGF expression in a hepatocellular carcinoma cell line. Int J Mol Med. 2011;28(3):449\u201354.","journal-title":"Int J Mol Med"},{"issue":"5","key":"1864_CR53","first-page":"2697","volume":"22","author":"A Horiuchi","year":"2002","unstructured":"Horiuchi A, Imai T, Shimizu M, et al. Hypoxia-induced changes in the expression of VEGF, HIF-1 alpha and cell cycle-related molecules in ovarian cancer cells. Anticancer Res. 2002;22(5):2697\u2013702.","journal-title":"Anticancer Res"},{"issue":"1","key":"1864_CR54","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3892\/or.2015.4354","volume":"35","author":"Z He","year":"2016","unstructured":"He Z, Chen AY, Rojanasakul Y, et al. Gallic acid, a phenolic compound, exerts anti-angiogenic effects via the PTEN\/AKT\/HIF-1\u03b1\/VEGF signaling pathway in ovarian cancer cells. Oncol Rep. 2016;35(1):291\u20137.","journal-title":"Oncol Rep"},{"issue":"10","key":"1864_CR55","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1054\/bjoc.2001.1805","volume":"84","author":"K Clarke","year":"2001","unstructured":"Clarke K, Smith K, Gullick WJ, et al. Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway. Br J Cancer. 2001;84(10):1322\u20139.","journal-title":"Br J Cancer"},{"issue":"1","key":"1864_CR56","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1136\/gut.48.1.87","volume":"48","author":"Z von Marschall","year":"2001","unstructured":"von Marschall Z, Cramer T, H\u00f6cker M, et al. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut. 2001;48(1):87\u201396.","journal-title":"Gut"},{"key":"1864_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.758386","volume":"12","author":"X Zhang","year":"2021","unstructured":"Zhang X, Hsueh MF, Huebner JL, et al. TNF-\u03b1 carried by plasma extracellular vesicles predicts knee osteoarthritis progression. Front Immunol. 2021;12:758386.","journal-title":"Front Immunol"},{"key":"1864_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/ani12212935","author":"WR He","year":"2022","unstructured":"He WR, Yuan J, Ma YH, et al. Modulation of host antiviral innate immunity by African swine fever virus: a review. Animals. 2022. https:\/\/doi.org\/10.3390\/ani12212935.","journal-title":"Animals"},{"issue":"45","key":"1864_CR59","doi-asserted-by":"publisher","first-page":"13862","DOI":"10.1039\/c2dt30662j","volume":"41","author":"S Romanski","year":"2012","unstructured":"Romanski S, Kraus B, Guttentag M, et al. Acyloxybutadiene tricarbonyl iron complexes as enzyme-triggered CO-releasing molecules (ET-CORMs): a structure-activity relationship study. Dalton Trans. 2012;41(45):13862\u201375.","journal-title":"Dalton Trans"},{"issue":"5","key":"1864_CR60","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1248\/bpb.b21-00691","volume":"45","author":"Y Liu","year":"2022","unstructured":"Liu Y, Cao Y, Kai H, et al. Polyphyllin E inhibits proliferation, migration and invasion of ovarian cancer cells by down-regulating the AKT\/NF-\u03baB pathway. Biol Pharm Bull. 2022;45(5):561\u20138.","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"1864_CR61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41588-023-01598-2","volume":"56","author":"ET Fok","year":"2024","unstructured":"Fok ET, Moorlag S, Negishi Y, et al. A chromatin-regulated biphasic circuit coordinates IL-1\u03b2-mediated inflammation. Nat Genet. 2024;56(1):85\u201399.","journal-title":"Nat Genet"},{"key":"1864_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076488","author":"IM Cumbres-Vargas","year":"2023","unstructured":"Cumbres-Vargas IM, Zamudio SR, Pichardo-Mac\u00edas LA, et al. Thalidomide attenuates epileptogenesis and seizures by decreasing brain inflammation in lithium pilocarpine rat model. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24076488.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1864_CR63","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1073\/pnas.0700118104","volume":"104","author":"T Lu","year":"2007","unstructured":"Lu T, Tian L, Han Y, et al. Dose-dependent cross-talk between the transforming growth factor-beta and interleukin-1 signaling pathways. Proc Natl Acad Sci U S A. 2007;104(11):4365\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1864_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01398-5","volume":"22","author":"MJ Iqbal","year":"2024","unstructured":"Iqbal MJ, Kabeer A, Abbas Z, et al. Interplay of oxidative stress, cellular communication and signaling pathways in cancer. Cell Commun Signal. 2024;22(1):7.","journal-title":"Cell Commun Signal"},{"issue":"2","key":"1864_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13020200","volume":"13","author":"E Supruniuk","year":"2024","unstructured":"Supruniuk E, Baczewska M, \u017bebrowska E, et al. Redox biomarkers and matrix remodeling molecules in ovarian cancer. Antioxidants. 2024;13(2):200.","journal-title":"Antioxidants"},{"issue":"22","key":"1864_CR66","doi-asserted-by":"publisher","first-page":"10823","DOI":"10.1158\/0008-5472.CAN-07-0783","volume":"67","author":"C Xia","year":"2007","unstructured":"Xia C, Meng Q, Liu LZ, et al. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res. 2007;67(22):10823\u201330.","journal-title":"Cancer Res"},{"issue":"16","key":"1864_CR67","doi-asserted-by":"publisher","first-page":"5106","DOI":"10.1128\/MCB.00060-08","volume":"28","author":"AA Qutub","year":"2008","unstructured":"Qutub AA, Popel AS. Reactive oxygen species regulate hypoxia-inducible factor 1alpha differentially in cancer and ischemia. Mol Cell Biol. 2008;28(16):5106\u201319.","journal-title":"Mol Cell Biol"},{"issue":"7","key":"1864_CR68","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1172\/JCI118962","volume":"98","author":"M Kuroki","year":"1996","unstructured":"Kuroki M, Voest EE, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest. 1996;98(7):1667\u201375.","journal-title":"J Clin Invest"},{"key":"1864_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030623","author":"Y Chen","year":"2023","unstructured":"Chen Y, Le\u00f3n-Letelier RA, Abdel Sater AH, et al. c-MYC-driven polyamine metabolism in ovarian cancer: from pathogenesis to early detection and therapy. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15030623.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"1864_CR70","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/sj.onc.1208251","volume":"24","author":"P Mezquita","year":"2005","unstructured":"Mezquita P, Parghi SS, Brandvold KA, et al. Myc regulates VEGF production in B cells by stimulating initiation of VEGF mRNA translation. Oncogene. 2005;24(5):889\u2013901.","journal-title":"Oncogene"},{"issue":"2","key":"1864_CR71","doi-asserted-by":"publisher","first-page":"983","DOI":"10.3390\/ijms12020983","volume":"12","author":"MJ Kwon","year":"2011","unstructured":"Kwon MJ, Shin YK. Epigenetic regulation of cancer-associated genes in ovarian cancer. Int J Mol Sci. 2011;12(2):983\u20131008.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1864_CR72","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.4161\/cbt.6.12.4976","volume":"6","author":"D Matei","year":"2007","unstructured":"Matei D, Kelich S, Cao L, et al. PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biol Ther. 2007;6(12):1951\u20139.","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"1864_CR73","doi-asserted-by":"publisher","first-page":"511","DOI":"10.21873\/cgp.20014","volume":"13","author":"AM Cimpean","year":"2016","unstructured":"Cimpean AM, Cobec IM, Ceau\u0219u RA, et al. Platelet derived growth factor BB: A Must-have therapeutic target redivivus in ovarian cancer. Cancer Genomics Proteom. 2016;13(6):511\u20137.","journal-title":"Cancer Genomics Proteom"},{"issue":"3","key":"1864_CR74","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s12276-020-0396-y","volume":"52","author":"L Fang","year":"2020","unstructured":"Fang L, Li Y, Wang S, et al. TGF-\u03b21 induces VEGF expression in human granulosa-lutein cells: a potential mechanism for the pathogenesis of ovarian hyperstimulation syndrome. Exp Mol Med. 2020;52(3):450\u201360.","journal-title":"Exp Mol Med"},{"issue":"2","key":"1864_CR75","first-page":"657","volume":"43","author":"YM Salinas-Vera","year":"2019","unstructured":"Salinas-Vera YM, Marchat LA, Gallardo-Rinc\u00f3n D, et al. AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review). Int J Mol Med. 2019;43(2):657\u201370.","journal-title":"Int J Mol Med"},{"issue":"2","key":"1864_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056647","volume":"8","author":"J He","year":"2013","unstructured":"He J, Jing Y, Li W, et al. Roles and mechanism of miR-199a and miR-125b in tumor angiogenesis. PLoS One. 2013;8(2):e56647.","journal-title":"PLoS One"},{"key":"1864_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00143","volume":"4","author":"Y Wang","year":"2014","unstructured":"Wang Y, Kim S, Kim IM. Regulation of metastasis by micrornas in ovarian cancer. Front Oncol. 2014;4:143.","journal-title":"Front Oncol"},{"issue":"11","key":"1864_CR78","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/bjc.2012.468","volume":"107","author":"NG Gavalas","year":"2012","unstructured":"Gavalas NG, Tsiatas M, Tsitsilonis O, et al. VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br J Cancer. 2012;107(11):1869\u201375.","journal-title":"Br J Cancer"},{"issue":"4","key":"1864_CR79","first-page":"4457","volume":"15","author":"K Wang","year":"2018","unstructured":"Wang K, Guan C, Fang C, et al. Clinical significance and prognostic value of forkhead box A1 expression in human epithelial ovarian cancer. Oncol Lett. 2018;15(4):4457\u201362.","journal-title":"Oncol Lett"},{"issue":"3","key":"1864_CR80","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3892\/ijo.2016.3333","volume":"48","author":"I Skirnisdottir","year":"2016","unstructured":"Skirnisdottir I, Seidal T, \u00c5kerud H. The relationship of the angiogenesis regulators VEGF-A, VEGF-R1 and VEGF-R2 to p53 status and prognostic factors in epithelial ovarian carcinoma in FIGO-stages I-II. Int J Oncol. 2016;48(3):998\u20131006.","journal-title":"Int J Oncol"},{"issue":"2","key":"1864_CR81","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0304-3835(97)00350-9","volume":"121","author":"EM Hartenbach","year":"1997","unstructured":"Hartenbach EM, Olson TA, Goswitz JJ, et al. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett. 1997;121(2):169\u201375.","journal-title":"Cancer Lett"},{"issue":"5","key":"1864_CR82","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1054\/bjoc.2000.1319","volume":"83","author":"JA Loncaster","year":"2000","unstructured":"Loncaster JA, Cooper RA, Logue JP, et al. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer. 2000;83(5):620\u20135.","journal-title":"Br J Cancer"},{"key":"1864_CR83","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.2147\/OTT.S132558","volume":"10","author":"AM Mahecha","year":"2017","unstructured":"Mahecha AM, Wang H. The influence of vascular endothelial growth factor-A and matrix metalloproteinase-2 and \u2013 9 in angiogenesis, metastasis, and prognosis of endometrial cancer. Onco Targets Ther. 2017;10:4617\u201324.","journal-title":"Onco Targets Ther"},{"key":"1864_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.843250","volume":"12","author":"Z Kong","year":"2022","unstructured":"Kong Z, Sun F, Meng Q, et al. Investigating the predictive value of vascular endothelial growth factor in the evaluation of treatment efficacy and prognosis for patients with non-surgical esophageal squamous cell carcinoma. Front Oncol. 2022;12:843250.","journal-title":"Front Oncol"},{"issue":"9","key":"1864_CR85","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/sj.bjc.6605017","volume":"100","author":"SJ Schoenleber","year":"2009","unstructured":"Schoenleber SJ, Kurtz DM, Talwalkar JA, et al. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer. 2009;100(9):1385\u201392.","journal-title":"Br J Cancer"},{"issue":"12","key":"1864_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004051","volume":"3","author":"M Mendiola","year":"2008","unstructured":"Mendiola M, Barriuso J, Redondo A, et al. Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma. PLoS ONE. 2008;3(12):e4051.","journal-title":"PLoS ONE"},{"issue":"6","key":"1864_CR87","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1007\/s13277-015-3050-x","volume":"36","author":"B Dobrzycka","year":"2015","unstructured":"Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM, et al. Prognostic significance of pretreatment VEGF, survivin, and Smac\/DIABLO serum levels in patients with serous ovarian carcinoma. Tumour Biol. 2015;36(6):4157\u201365.","journal-title":"Tumour Biol"},{"issue":"8","key":"1864_CR88","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1158\/1535-7163.MCT-10-0169","volume":"9","author":"S Mabuchi","year":"2010","unstructured":"Mabuchi S, Kawase C, Altomare DA, et al. Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther. 2010;9(8):2411\u201322.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1864_CR89","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ygyno.2003.08.022","volume":"91","author":"C Wong","year":"2003","unstructured":"Wong C, Wellman TL, Lounsbury KM. VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol. 2003;91(3):513\u20137.","journal-title":"Gynecol Oncol"},{"key":"1864_CR90","unstructured":"Wang XC. Research progress of molecular indicators related to metastasis of ovarian cancer. J Chengde Med Coll. 2006;(02):171\u20133."},{"issue":"4","key":"1864_CR91","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3109\/00365513.2013.773593","volume":"73","author":"B Liang","year":"2013","unstructured":"Liang B, Guo Z, Li Y, et al. Elevated VEGF concentrations in ascites and serum predict adverse prognosis in ovarian cancer. Scand J Clin Lab Invest. 2013;73(4):309\u201314.","journal-title":"Scand J Clin Lab Invest"},{"issue":"2","key":"1864_CR92","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1158\/0008-5472.465.65.2","volume":"65","author":"I Kryczek","year":"2005","unstructured":"Kryczek I, Lange A, Mottram P, et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 2005;65(2):465\u201372.","journal-title":"Cancer Res"},{"key":"1864_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1234104","volume":"14","author":"W Nan","year":"2023","unstructured":"Nan W, He Y, Wang S, et al. Molecular mechanism of VE-cadherin in regulating endothelial cell behaviour during angiogenesis. Front Physiol. 2023;14:1234104.","journal-title":"Front Physiol"},{"issue":"6","key":"1864_CR94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067438","volume":"8","author":"WH Tan","year":"2013","unstructured":"Tan WH, Popel AS, Mac Gabhann F. Computational model of Gab1\/2-dependent VEGFR2 pathway to Akt activation. PLoS ONE. 2013;8(6):e67438.","journal-title":"PLoS ONE"},{"key":"1864_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20081901","author":"T Alonso-Gordoa","year":"2019","unstructured":"Alonso-Gordoa T, Garc\u00eda-Bermejo ML, Grande E, et al. Targeting tyrosine kinases in renal cell carcinoma: new bullets against old guys. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20081901.","journal-title":"Int J Mol Sci"},{"key":"1864_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01336","volume":"10","author":"HS Tuli","year":"2019","unstructured":"Tuli HS, Tuorkey MJ, Thakral F, et al. Molecular mechanisms of action of genistein in cancer: recent advances. Front Pharmacol. 2019;10:1336.","journal-title":"Front Pharmacol"},{"key":"1864_CR97","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026609","author":"BA Hemmings","year":"2015","unstructured":"Hemmings BA, Restuccia DF. The PI3K-PKB\/Akt pathway. Cold Spring Harb Perspect Biol. 2015. https:\/\/doi.org\/10.1101\/cshperspect.a026609.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"4","key":"1864_CR98","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1530\/JME-16-0239","volume":"58","author":"Y Xing","year":"2017","unstructured":"Xing Y, Lai J, Liu X, et al. Netrin-1 restores cell injury and impaired angiogenesis in vascular endothelial cells upon high glucose by PI3K\/AKT-eNOS. J Mol Endocrinol. 2017;58(4):167\u201377.","journal-title":"J Mol Endocrinol"},{"issue":"2","key":"1864_CR99","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/jb\/mvu077","volume":"157","author":"S Aikawa","year":"2015","unstructured":"Aikawa S, Hashimoto T, Kano K, et al. Lysophosphatidic acid as a lipid mediator with multiple biological actions. J Biochem. 2015;157(2):81\u20139.","journal-title":"J Biochem"},{"issue":"3","key":"1864_CR100","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/apha.12622","volume":"216","author":"X Chen","year":"2016","unstructured":"Chen X, Walther FJ, van Boxtel R, et al. Deficiency or inhibition of lysophosphatidic acid receptor 1 protects against hyperoxia-induced lung injury in neonatal rats. Acta Physiol (Oxf). 2016;216(3):358\u201375.","journal-title":"Acta Physiol (Oxf)"},{"issue":"5","key":"1864_CR101","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/cmdc.200600280","volume":"2","author":"G Jiang","year":"2007","unstructured":"Jiang G, Xu Y, Fujiwara Y, et al. Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. ChemMedChem. 2007;2(5):679\u201390.","journal-title":"ChemMedChem"},{"issue":"10","key":"1864_CR102","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/jnci\/93.10.762","volume":"93","author":"YL Hu","year":"2001","unstructured":"Hu YL, Tee MK, Goetzl EJ, et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst. 2001;93(10):762\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"1864_CR103","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.7150\/ijbs.70958","volume":"18","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Guo S, Deng J, et al. VEGF\/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment. Int J Biol Sci. 2022;18(9):3845\u201358.","journal-title":"Int J Biol Sci"},{"issue":"9","key":"1864_CR104","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1128\/MCB.16.9.4604","volume":"16","author":"JA Forsythe","year":"1996","unstructured":"Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16(9):4604\u201313.","journal-title":"Mol Cell Biol"},{"issue":"12","key":"1864_CR105","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1128\/MCB.21.12.3995-4004.2001","volume":"21","author":"E Laughner","year":"2001","unstructured":"Laughner E, Taghavi P, Chiles K, et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001;21(12):3995\u20134004.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"1864_CR106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019139","volume":"6","author":"LZ Liu","year":"2011","unstructured":"Liu LZ, Li C, Chen Q, et al. Mir-21 induced angiogenesis through AKT and ERK activation and HIF-1\u03b1 expression. PLoS ONE. 2011;6(4):e19139.","journal-title":"PLoS ONE"},{"issue":"42","key":"1864_CR107","doi-asserted-by":"publisher","first-page":"32116","DOI":"10.1074\/jbc.M110.131284","volume":"285","author":"YK Choi","year":"2010","unstructured":"Choi YK, Kim CK, Lee H, et al. Carbon monoxide promotes VEGF expression by increasing HIF-1alpha protein level via two distinct mechanisms, translational activation and stabilization of HIF-1alpha protein. J Biol Chem. 2010;285(42):32116\u201325.","journal-title":"J Biol Chem"},{"issue":"3","key":"1864_CR108","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1054\/bjoc.2001.1933","volume":"85","author":"J Fujimoto","year":"2001","unstructured":"Fujimoto J, Sakaguchi H, Aoki I, et al. Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers. Br J Cancer. 2001;85(3):313\u20136.","journal-title":"Br J Cancer"},{"key":"1864_CR109","first-page":"59","volume":"8","author":"EC McClung","year":"2016","unstructured":"McClung EC, Wenham RM. Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives. Int J Womens Health. 2016;8:59\u201375.","journal-title":"Int J Womens Health"},{"issue":"2","key":"1864_CR110","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/joim.12019","volume":"273","author":"L Claesson-Welsh","year":"2013","unstructured":"Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273(2):114\u201327.","journal-title":"J Intern Med"},{"key":"1864_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9121789","author":"JP Shiau","year":"2021","unstructured":"Shiau JP, Wu CC, Chang SJ, et al. FAK regulates VEGFR2 expression and promotes angiogenesis in Triple-Negative breast cancer. Biomedicines. 2021. https:\/\/doi.org\/10.3390\/biomedicines9121789.","journal-title":"Biomedicines"},{"key":"1864_CR112","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.bone.2016.06.013","volume":"91","author":"K Hu","year":"2016","unstructured":"Hu K, Olsen BR. The roles of vascular endothelial growth factor in bone repair and regeneration. Bone. 2016;91:30\u20138.","journal-title":"Bone"},{"issue":"35","key":"1864_CR113","doi-asserted-by":"publisher","first-page":"23217","DOI":"10.1074\/jbc.M109.019679","volume":"284","author":"Y Xiong","year":"2009","unstructured":"Xiong Y, Huo Y, Chen C, et al. Vascular endothelial growth factor (VEGF) receptor-2 tyrosine 1175 signaling controls VEGF-induced von Willebrand factor release from endothelial cells via phospholipase C-gamma 1- and protein kinase A-dependent pathways. J Biol Chem. 2009;284(35):23217\u201324.","journal-title":"J Biol Chem"},{"issue":"3","key":"1864_CR114","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1183\/09031936.00125007","volume":"31","author":"KS Lee","year":"2008","unstructured":"Lee KS, Park SJ, Kim SR, et al. Inhibition of VEGF blocks TGF-beta1 production through a PI3K\/Akt signalling pathway. Eur Respir J. 2008;31(3):523\u201331.","journal-title":"Eur Respir J"},{"key":"1864_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0497-3","volume":"15","author":"I Bekes","year":"2016","unstructured":"Bekes I, Friedl TW, K\u00f6hler T. Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer? Mol Cancer. 2016;15:13.","journal-title":"Mol Cancer"},{"key":"1864_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1159061","volume":"14","author":"X Fu","year":"2023","unstructured":"Fu X, Wang Q, Du H, et al. CXCL8 and the peritoneal metastasis of ovarian and gastric cancer. Front Immunol. 2023;14:1159061.","journal-title":"Front Immunol"},{"key":"1864_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/cells8030270","author":"MC Hsu","year":"2019","unstructured":"Hsu MC, Pan MR, Hung WC. Two birds, one stone: double hits on tumor growth and lymphangiogenesis by targeting vascular endothelial growth factor receptor 3. Cells. 2019. https:\/\/doi.org\/10.3390\/cells8030270.","journal-title":"Cells"},{"issue":"1","key":"1864_CR118","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1451-2","volume":"15","author":"Y Xu","year":"2015","unstructured":"Xu Y, Lu W, Yang P, et al. A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities. BMC Cancer. 2015;15(1):525.","journal-title":"BMC Cancer"},{"key":"1864_CR119","doi-asserted-by":"publisher","DOI":"10.3390\/cells12020319","author":"M Patnam","year":"2023","unstructured":"Patnam M, Dommaraju SR, Masood F, et al. Lymphangiogenesis guidance mechanisms and therapeutic implications in pathological states of the cornea. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12020319.","journal-title":"Cells"},{"issue":"6","key":"1864_CR120","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1172\/JCI83967","volume":"126","author":"HM Bui","year":"2016","unstructured":"Bui HM, Enis D, Robciuc MR, et al. Proteolytic activation defines distinct lymphangiogenic mechanisms for VEGFC and VEGFD. J Clin Invest. 2016;126(6):2167\u201380.","journal-title":"J Clin Invest"},{"issue":"1","key":"1864_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04982-1","volume":"7","author":"SK Jha","year":"2017","unstructured":"Jha SK, Rauniyar K, Karpanen T, et al. Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1. Sci Rep. 2017;7(1):4916.","journal-title":"Sci Rep"},{"issue":"1","key":"1864_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/biom13010103","volume":"13","author":"E Lopez","year":"2023","unstructured":"Lopez E, Kamboj S, Chen C, et al. In vitro models of ovarian cancer: bridging the gap between pathophysiology and mechanistic models. Biomolecules. 2023;13(1):103.","journal-title":"Biomolecules"},{"issue":"9","key":"1864_CR123","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/cas.12987","volume":"107","author":"S Kim","year":"2016","unstructured":"Kim S, Kim B, Song YS. Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer. Cancer Sci. 2016;107(9):1173\u20138.","journal-title":"Cancer Sci"},{"issue":"15","key":"1864_CR124","first-page":"5721","volume":"9","author":"AT Byrne","year":"2003","unstructured":"Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res. 2003;9(15):5721\u20138.","journal-title":"Clin Cancer Res"},{"key":"1864_CR125","unstructured":"Committee of Gynecological Oncology of Chinese Anti-Cancer Association. Chinese Guidelines for Maintenance Treatment of Epithelial Ovarian Cancer. (2022 edition). Chinese Journal of Applied Gynecology and Obstetrics. 2022;38(01):56\u201365."},{"key":"1864_CR126","doi-asserted-by":"publisher","DOI":"10.1186\/1757-2215-7-57","volume":"7","author":"G Aravantinos","year":"2014","unstructured":"Aravantinos G, Pectasides D. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review. J Ovarian Res. 2014;7:57.","journal-title":"J Ovarian Res"},{"issue":"17","key":"1864_CR127","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, et al. Oceans: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039\u201345.","journal-title":"J Clin Oncol"},{"issue":"26","key":"1864_CR128","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473\u201383.","journal-title":"N Engl J Med"},{"key":"1864_CR129","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.2147\/CMAR.S366681","volume":"14","author":"M Algethami","year":"2022","unstructured":"Algethami M, Kulkarni S, Sadiq MT, et al. Towards personalized management of ovarian cancer. Cancer Manag Res. 2022;14:3469\u201383.","journal-title":"Cancer Manag Res"},{"key":"1864_CR130","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.711813","volume":"12","author":"D Berton","year":"2021","unstructured":"Berton D, Floquet A, Lescaut W. Real-world experience of bevacizumab as first-line treatment for ovarian cancer: the GINECO encourage cohort of 468 French patients. Front Pharmacol. 2021;12:711813.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1864_CR131","doi-asserted-by":"publisher","first-page":"10703","DOI":"10.18632\/oncotarget.12926","volume":"8","author":"YS Wu","year":"2017","unstructured":"Wu YS, Shui L, Shen D, et al. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials. Oncotarget. 2017;8(6):10703\u201313.","journal-title":"Oncotarget"},{"key":"1864_CR132","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1064472","volume":"13","author":"RR Naik","year":"2022","unstructured":"Naik RR, Shakya AK. Exploring the chemotherapeutic potential of currently used kinase inhibitors: an update. Front Pharmacol. 2022;13:1064472.","journal-title":"Front Pharmacol"},{"issue":"30","key":"1864_CR133","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","volume":"32","author":"A du Bois","year":"2014","unstructured":"du Bois A, Floquet A, Kim JW, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32(30):3374\u201382.","journal-title":"J Clin Oncol"},{"key":"1864_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091357","author":"P Katopodis","year":"2019","unstructured":"Katopodis P, Chudasama D, Wander G, et al. Kinase inhibitors and ovarian cancer. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11091357.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"1864_CR135","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3892\/ijo.2014.2334","volume":"44","author":"V Conteduca","year":"2014","unstructured":"Conteduca V, Kopf B, Burgio SL, et al. The emerging role of anti-angiogenic therapy in ovarian cancer (review). Int J Oncol. 2014;44(5):1417\u201324.","journal-title":"Int J Oncol"},{"issue":"1","key":"1864_CR136","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ygyno.2020.07.031","volume":"159","author":"JM Lee","year":"2020","unstructured":"Lee JM, Annunziata CM, Hays JL, et al. Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment. Gynecol Oncol. 2020;159(1):88\u201394.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"1864_CR137","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1158\/1078-0432.CCR-10-3314","volume":"17","author":"MS Anglesio","year":"2011","unstructured":"Anglesio MS, George J, Kulbe H, et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor Sunitinib in ovarian clear cell cancer. Clin Cancer Res. 2011;17(8):2538\u201348.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1864_CR138","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","volume":"99","author":"J Holash","year":"2002","unstructured":"Holash J, Davis S, Papadopoulos N, et al. VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1864_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10010077","author":"MP Garrido","year":"2021","unstructured":"Garrido MP, Fredes AN, Lobos-Gonz\u00e1lez L, et al. Current treatments and new possible complementary therapies for epithelial ovarian cancer. Biomedicines. 2021. https:\/\/doi.org\/10.3390\/biomedicines10010077.","journal-title":"Biomedicines"},{"issue":"13","key":"1864_CR140","doi-asserted-by":"publisher","first-page":"7785","DOI":"10.1073\/pnas.1432908100","volume":"100","author":"J Huang","year":"2003","unstructured":"Huang J, Frischer JS, Serur A, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A. 2003;100(13):7785\u201390.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1864_CR141","doi-asserted-by":"publisher","first-page":"e4771","DOI":"10.1016\/j.ajog.2007.12.028","volume":"198","author":"C Lu","year":"2008","unstructured":"Lu C, Thaker PH, Lin YG, et al. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol. 2008;198(4):e4771\u20139. discussion.e9-10.","journal-title":"Am J Obstet Gynecol"},{"issue":"33","key":"1864_CR142","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","volume":"27","author":"UA Matulonis","year":"2009","unstructured":"Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009;27(33):5601\u20136.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1864_CR143","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1517\/13543784.2016.1156857","volume":"25","author":"SP Ivy","year":"2016","unstructured":"Ivy SP, Liu JF, Lee JM, et al. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. Expert Opin Investig Drugs. 2016;25(5):597\u2013611.","journal-title":"Expert Opin Investig Drugs"},{"issue":"11","key":"1864_CR144","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","volume":"15","author":"JF Liu","year":"2014","unstructured":"Liu JF, Barry WT, Birrer M, et al. Combination cediranib and Olaparib versus Olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15(11):1207\u201314.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1864_CR145","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013770","volume":"5","author":"D Van Simaeys","year":"2010","unstructured":"Van Simaeys D, L\u00f3pez-Col\u00f3n D, Sefah K, et al. Study of the molecular recognition of aptamers selected through ovarian cancer cell-SELEX. PLoS ONE. 2010;5(11):e13770.","journal-title":"PLoS ONE"},{"key":"1864_CR146","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076315","author":"RDS Abreu","year":"2023","unstructured":"Abreu RDS, Antunes D, Moreira ADS, et al. Next generation of ovarian cancer detection using aptamers. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24076315.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1864_CR147","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1159\/000495925","volume":"51","author":"F Li","year":"2018","unstructured":"Li F, Wang Q, Zhang H, et al. Characterization of a DNA aptamer for ovarian cancer clinical tissue recognition and in vivo imaging. Cell Physiol Biochem. 2018;51(6):2564\u201374.","journal-title":"Cell Physiol Biochem"},{"key":"1864_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.884405","volume":"10","author":"J Zhao","year":"2022","unstructured":"Zhao J, Tan W, Zheng J, et al. Aptamer nanomaterials for ovarian cancer target theranostics. Front Bioeng Biotechnol. 2022;10:884405.","journal-title":"Front Bioeng Biotechnol"},{"issue":"11","key":"1864_CR149","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1158\/1078-0432.CCR-24-3368","volume":"31","author":"S Banerjee","year":"2025","unstructured":"Banerjee S, Ghisoni E, Wolfer A, et al. Bevacizumab, atezolizumab, and acetylsalicylic acid in recurrent, platinum-resistant ovarian cancer: the EORTC 1508-GCG phase II study. Clin Cancer Res. 2025;31(11):2145\u201353.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1864_CR150","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.4103\/jfmpc.jfmpc_2140_22","volume":"12","author":"A Tauseef","year":"2023","unstructured":"Tauseef A, Zafar M, Abodunrin F, et al. Bevacizumab combined with platinum-based chemotherapy in primary or relapsed ovarian cancer patients: meta-analysis and literature to review. J Fam Med Prim Care. 2023;12(11):2797\u2013804.","journal-title":"J Fam Med Prim Care"},{"issue":"1","key":"1864_CR151","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-023-02879-y","volume":"24","author":"D Huang","year":"2024","unstructured":"Huang D, Ke L, Cui H, et al. Efficacy and safety of VEGF\/VEGFR inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials. BMC Womens Health. 2024;24(1):34.","journal-title":"BMC Womens Health"},{"issue":"3","key":"1864_CR152","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3892\/ol.2012.553","volume":"3","author":"DT Rein","year":"2012","unstructured":"Rein DT, Volkmer AK, Volkmer J, et al. Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer. Oncol Lett. 2012;3(3):530\u20134.","journal-title":"Oncol Lett"},{"issue":"3","key":"1864_CR153","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2217\/imt.15.126","volume":"8","author":"T Hato","year":"2016","unstructured":"Hato T, Zhu AX, Duda DG. Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. Immunotherapy. 2016;8(3):299\u2013313.","journal-title":"Immunotherapy"},{"issue":"19","key":"1864_CR154","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1200\/JCO.2016.72.1340","volume":"35","author":"JM Lee","year":"2017","unstructured":"Lee JM, Cimino-Mathews A, Peer CJ, et al. Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-ribose) polymerase inhibitor Olaparib or vascular endothelial growth factor receptor 1\u20133 inhibitor cediranib in women\u2019s cancers: a dose-escalation, phase I study. J Clin Oncol. 2017;35(19):2193\u2013202.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1864_CR155","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","volume":"5","author":"JF Liu","year":"2019","unstructured":"Liu JF, Herold C, Gray KP, et al. Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial. JAMA Oncol. 2019;5(12):1731\u20138.","journal-title":"JAMA Oncol"},{"key":"1864_CR156","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1441222","volume":"14","author":"Y Xie","year":"2024","unstructured":"Xie Y, Xiao D, Li D, et al. Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer. Front Oncol. 2024;14:1441222.","journal-title":"Front Oncol"},{"issue":"1","key":"1864_CR157","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01196-x","volume":"14","author":"F Bizzaro","year":"2021","unstructured":"Bizzaro F, Fuso Nerini I, Taylor MA, et al. VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status. J Hematol Oncol. 2021;14(1):186.","journal-title":"J Hematol Oncol"},{"key":"1864_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2025.112598","volume":"607","author":"LS Lamb","year":"2025","unstructured":"Lamb LS, Sim HW, Ramus SJ, et al. Aggressive pituitary tumours and pituitary carcinomas: molecular insights guiding management and the role of precision oncology. Mol Cell Endocrinol. 2025;607:112598.","journal-title":"Mol Cell Endocrinol"},{"issue":"8","key":"1864_CR159","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41571-025-01035-9","volume":"22","author":"S Zhao","year":"2025","unstructured":"Zhao S, Zhao H, Yang W, et al. The next generation of immunotherapies for lung cancers. Nat Rev Clin Oncol. 2025;22(8):592\u2013616.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1864_CR160","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1136\/ijgc-2022-003719","volume":"33","author":"C Marques","year":"2023","unstructured":"Marques C, Ferreira da Silva F, Sousa I, et al. Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality? Int J Gynecol Cancer. 2023;33(4):607\u201318.","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"1864_CR161","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/s44321-024-00094-2","volume":"16","author":"Y Tai","year":"2024","unstructured":"Tai Y, Chow A, Han S, et al. FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer. EMBO Mol Med. 2024;16(8):1957\u201380.","journal-title":"EMBO Mol Med"},{"issue":"3","key":"1864_CR162","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1124\/jpet.122.001255","volume":"384","author":"I Hofmann","year":"2023","unstructured":"Hofmann I, Baum A, Hofmann MH, et al. Pharmacodynamic and antitumor activity of BI 836880, a dual vascular endothelial growth factor and angiopoietin 2 inhibitor, alone and combined with programmed cell death protein-1 inhibition. J Pharmacol Exp Ther. 2023;384(3):331\u201342.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"1864_CR163","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/cac2.12539","volume":"44","author":"GR Khosravi","year":"2024","unstructured":"Khosravi GR, Mostafavi S, Bastan S, et al. Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Commun. 2024;44(5):521\u201353.","journal-title":"Cancer Commun"},{"issue":"1","key":"1864_CR164","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, et al. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9(1):274.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1864_CR165","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54145-w","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, Venet D, Lifrange F, et al. Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications. Nat Commun. 2024;15(1):10232.","journal-title":"Nat Commun"},{"key":"1864_CR166","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1506499","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, Liu M, Wu Y, et al. Gentiopicroside targeting AKT1 activates HIF-1\u03b1\/VEGF axis promoting diabetic ulcer wound healing. Front Pharmacol. 2025;16:1506499.","journal-title":"Front Pharmacol"},{"key":"1864_CR167","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315263","author":"S Zhan","year":"2022","unstructured":"Zhan S, Yung MMH, Siu MKY, et al. New insights into ferroptosis initiating therapies (FIT) by targeting the rewired lipid metabolism in ovarian cancer peritoneal metastases. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232315263.","journal-title":"Int J Mol Sci"},{"key":"1864_CR168","doi-asserted-by":"publisher","DOI":"10.3390\/biom13071135","author":"X Zheng","year":"2023","unstructured":"Zheng X, Diktonaite K, Qiu H. Epigenetic reader bromodomain-containing protein 4 in aging-related vascular pathologies and diseases: molecular basis, functional relevance, and clinical potential. Biomolecules. 2023. https:\/\/doi.org\/10.3390\/biom13071135.","journal-title":"Biomolecules"},{"key":"1864_CR169","unstructured":"Phase I\/Ib Trial Evaluating the Safety and Efficacy of BET Inhibitor, ZEN003694 With PD-1 Inhibitor, Nivolumab With or Without CTLA-4 Inhibitor, Ipilimumab in Solid Tumors. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04840589."},{"issue":"1","key":"1864_CR170","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.bjc.6604767","volume":"100","author":"GC Kumaran","year":"2009","unstructured":"Kumaran GC, Jayson GC, Clamp AR. Antiangiogenic drugs in ovarian cancer. Br J Cancer. 2009;100(1):1\u20137.","journal-title":"Br J Cancer"},{"issue":"12","key":"1864_CR171","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S1470-2045(11)70244-3","volume":"12","author":"RL Coleman","year":"2011","unstructured":"Coleman RL, Duska LR, Ramirez PT, et al. Phase 1\u20132 study of docetaxel plus Aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol. 2011;12(12):1109\u201317.","journal-title":"Lancet Oncol"},{"key":"1864_CR172","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1402862","volume":"15","author":"Y Li","year":"2024","unstructured":"Li Y, Li XM, Yang KD, et al. Advancements in ovarian cancer immunodiagnostics and therapeutics via phage display technology. Front Immunol. 2024;15:1402862.","journal-title":"Front Immunol"},{"key":"1864_CR173","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020416","author":"M K\u00f6bel","year":"2022","unstructured":"K\u00f6bel M, Kang EY. The evolution of ovarian carcinoma subclassification. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14020416.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1864_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106020","volume":"26","author":"D Glassman","year":"2023","unstructured":"Glassman D, Kim MS, Spradlin M, et al. Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer. iScience. 2023;26(2):106020.","journal-title":"iScience"},{"issue":"44","key":"1864_CR175","doi-asserted-by":"publisher","first-page":"e2204436","DOI":"10.1002\/smll.202204436","volume":"18","author":"T Korzun","year":"2022","unstructured":"Korzun T, Moses AS, Kim J, et al. Nanoparticle-Based follistatin messenger RNA therapy for reprogramming metastatic ovarian cancer and ameliorating cancer-Associated cachexia. Small. 2022;18(44):e2204436.","journal-title":"Small"},{"key":"1864_CR176","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00867","volume":"10","author":"L Zhang","year":"2019","unstructured":"Zhang L, Chen Y, Li F, et al. Atezolizumab and bevacizumab attenuate cisplatin resistant ovarian cancer cells progression synergistically via suppressing epithelial-mesenchymal transition. Front Immunol. 2019;10:867.","journal-title":"Front Immunol"},{"issue":"6","key":"1864_CR177","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.12998\/wjcc.v12.i6.1190","volume":"12","author":"WL Hsieh","year":"2024","unstructured":"Hsieh WL, Ding DC. Management of retroperitoneal high-grade serous carcinoma of unknown origin: a case report. World J Clin Cases. 2024;12(6):1190\u20135.","journal-title":"World J Clin Cases"},{"issue":"7","key":"1864_CR178","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-024-05879-z","volume":"150","author":"SK Behera","year":"2024","unstructured":"Behera SK, Das A, Sethy PK. Deep fine-KNN classification of ovarian cancer subtypes using efficientNet-B0 extracted features: a comprehensive analysis. J Cancer Res Clin Oncol. 2024;150(7):361.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1864_CR179","doi-asserted-by":"publisher","DOI":"10.1186\/s40661-015-0008-z","volume":"2","author":"LP Cobb","year":"2015","unstructured":"Cobb LP, Gaillard S, Wang Y, et al. Adenocarcinoma of mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. Gynecol Oncol Res Pract. 2015;2:1.","journal-title":"Gynecol Oncol Res Pract"},{"issue":"1","key":"1864_CR180","first-page":"193","volume":"39","author":"K Fujikake","year":"2018","unstructured":"Fujikake K, Kajiyama H, Yoshihara M, et al. A novel mechanism of neovascularization in peritoneal dissemination via cancer-associated mesothelial cells affected by TGF-\u03b2 derived from ovarian cancer. Oncol Rep. 2018;39(1):193\u2013200.","journal-title":"Oncol Rep"},{"issue":"1","key":"1864_CR181","first-page":"69","volume":"31","author":"S Baritaki","year":"2007","unstructured":"Baritaki S, Sifakis S, Huerta-Yepez S, et al. Overexpression of VEGF and TGF-beta1 mRNA in pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection. Int J Oncol. 2007;31(1):69\u201379.","journal-title":"Int J Oncol"},{"issue":"3","key":"1864_CR182","first-page":"699","volume":"12","author":"K Katanyoo","year":"2011","unstructured":"Katanyoo K, Chantarasri A, Chongtanakon M, et al. Pretreatment levels of serum vascular endothelial growth factor do not correlate with outcome in patients with locally advanced cervical cancer. Asian Pac J Cancer Prev. 2011;12(3):699\u2013702.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"1864_CR183","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8040439","volume":"8","author":"HC Chiu","year":"2019","unstructured":"Chiu HC, Li CJ, Yiang GT, et al. Epithelial to mesenchymal transition and cell biology of molecular regulation in endometrial carcinogenesis. J Clin Med. 2019;8(4):439.","journal-title":"J Clin Med"},{"issue":"3","key":"1864_CR184","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ygyno.2015.06.036","volume":"138","author":"J Han","year":"2015","unstructured":"Han J, Zhang L, Guo H, et al. Glucose promotes cell proliferation, glucose uptake and invasion in endometrial cancer cells via AMPK\/mTOR\/S6 and MAPK signaling. Gynecol Oncol. 2015;138(3):668\u201375.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"1864_CR185","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1021\/acs.jmedchem.6b00975","volume":"60","author":"KM Nelson","year":"2017","unstructured":"Nelson KM, Dahlin JL, Bisson J, et al. The essential medicinal chemistry of Curcumin. J Med Chem. 2017;60(5):1620\u201337.","journal-title":"J Med Chem"},{"issue":"4","key":"1864_CR186","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.3892\/mmr.2017.7250","volume":"16","author":"H Cao","year":"2017","unstructured":"Cao H, Wei YX, Zhou Q, et al. Inhibitory effect of Curcumin in human endometriosis endometrial cells via downregulation of vascular endothelial growth factor. Mol Med Rep. 2017;16(4):5611\u20137.","journal-title":"Mol Med Rep"},{"issue":"2","key":"1864_CR187","doi-asserted-by":"publisher","first-page":"207","DOI":"10.17219\/acem\/31186","volume":"26","author":"G Kizilay","year":"2017","unstructured":"Kizilay G, Uz YH, Seren G, et al. In vivo effects of Curcumin and deferoxamine in experimental endometriosis. Adv Clin Exp Med. 2017;26(2):207\u201313.","journal-title":"Adv Clin Exp Med"},{"issue":"3","key":"1864_CR188","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3892\/ijmm.2017.2857","volume":"39","author":"M Sun","year":"2017","unstructured":"Sun M, Ye Y, Xiao L, et al. Anticancer effects of ginsenoside Rg3 (review). Int J Mol Med. 2017;39(3):507\u201318.","journal-title":"Int J Mol Med"},{"key":"1864_CR189","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.889799","volume":"13","author":"K Li","year":"2022","unstructured":"Li K, Xiao K, Zhu S, et al. Chinese herbal medicine for primary liver cancer therapy: perspectives and challenges. Front Pharmacol. 2022;13:889799.","journal-title":"Front Pharmacol"},{"issue":"11","key":"1864_CR190","doi-asserted-by":"publisher","first-page":"e0186520","DOI":"10.1371\/journal.pone.0186520","volume":"12","author":"Y Cao","year":"2017","unstructured":"Cao Y, Ye Q, Zhuang M, et al. Ginsenoside Rg3 inhibits angiogenesis in a rat model of endometriosis through the VEGFR-2-mediated PI3K\/Akt\/mTOR signaling pathway. PLoS ONE. 2017;12(11):e0186520.","journal-title":"PLoS ONE"},{"issue":"5","key":"1864_CR191","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.3892\/or.2017.6007","volume":"38","author":"YG Park","year":"2017","unstructured":"Park YG, Choi J, Jung HK, et al. Baicalein inhibits tumor progression by inhibiting tumor cell growth and tumor angiogenesis. Oncol Rep. 2017;38(5):3011\u20138.","journal-title":"Oncol Rep"},{"issue":"3","key":"1864_CR192","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1177\/1534735418775828","volume":"17","author":"C Zhang","year":"2018","unstructured":"Zhang C, Wang N, Tan HY, et al. Targeting VEGF\/VEGFRs pathway in the antiangiogenic treatment of human cancers by traditional Chinese medicine. Integr Cancer Ther. 2018;17(3):582\u2013601.","journal-title":"Integr Cancer Ther"},{"key":"1864_CR193","unstructured":"Sheng JJ, Li H,\u00a0Zheng Sa, et al. Curcumin enhances the sensitivity of PEO1 ovarian cancer cell line to niraparib by inhibiting the homologous recombination repair pathway. Zhoulouyaoxue. 15;(1):53\u201358+145."},{"issue":"07","key":"1864_CR194","first-page":"1415","volume":"39","author":"Y Yu","year":"2023","unstructured":"Yu Y, Zahng QG, Cui HZ, et al. Effects of Curcumin combined with cisplatin on Proliferation, Migration, and apoptosis of ovarian cancer Drug-resistant cells through regulation of the PI3K\/Akt signaling pathway. Chin J Immunol. 2023;39(07):1415\u20139.","journal-title":"Chin J Immunol"},{"key":"1864_CR195","unstructured":"Jiang Feng. Research on the mechanism of ginsenoside Rg3 in inhibiting the invasion of human ovarian cancer cell line SKOV3. Master's thesis of University of South China. 2015."},{"issue":"2","key":"1864_CR196","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11883-022-01078-8","volume":"25","author":"P Mohammadi-Shemirani","year":"2023","unstructured":"Mohammadi-Shemirani P, Sood T, Par\u00e9 G. From \u2018Omics to Multi-omics technologies: the discovery of novel causal mediators. Curr Atheroscler Rep. 2023;25(2):55\u201365.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"1864_CR197","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00643-4","volume":"12","author":"X Wu","year":"2024","unstructured":"Wu X, Yang X, Dai Y, et al. Single-cell sequencing to multi-omics: technologies and applications. Biomark Res. 2024;12(1):110.","journal-title":"Biomark Res"},{"issue":"3","key":"1864_CR198","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s13167-024-00376-2","volume":"15","author":"R Chen","year":"2024","unstructured":"Chen R, Wang X, Li N, et al. Body fluid multiomics in 3PM-guided ischemic stroke management: health risk assessment, targeted protection against health-to-disease transition, and cost-effective personalized approach are envisaged. EPMA J. 2024;15(3):415\u201352.","journal-title":"EPMA J"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01864-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01864-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01864-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T11:03:04Z","timestamp":1763550184000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-025-01864-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":198,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1864"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01864-3","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"4 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"272"}}